Arginase Inhibition Mitigates Bortezomib-Exacerbated Cardiotoxicity in Multiple Myeloma.

ABSTRACT:

Background

Multiple myeloma (MM) is associated with increased cardiovascular morbidity and mortality, while MM therapies also result in adverse cardiac effects. Endothelial dysfunction and impaired nitric oxide (NO) pathway is their possible mediator.

Objective

Since MM is associated with increased arginase expression, resulting in the consumption of ʟ-arginine, precursor for NO synthesis, our aim was to test if cardiotoxicity mediated by MM and MM therapeutic, bortezomib (a proteasome inhibitor), can be ameliorated by an arginase inhibitor through improved endothelial function.

Methods

We used a mouse Vĸ*MYC model of non-light chain MM. Cardiac function was assessed by echocardiography.

Results

MM resulted in progressive left ventricular (LV) systolic dysfunct

SUBMITTER: Paterek A 

PROVIDER: S-EPMC10093116 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature